Yukihide Kanemitsu1, Yasuhiro Shimizu2, Junki Mizusawa1, Yoshitaka Inaba2, Tetsuya Hamaguchi3, Dai Shida1, Masayuki Ohue4, Koji Komori2, Akio Shiomi5, Manabu Shiozawa6, Jun Watanabe7, Takeshi Suto8, Yusuke Kinugasa9, Yasumasa Takii10, Hiroyuki Bando11, Takaya Kobatake12, Masafumi Inomata13, Yasuhiro Shimada14, Hiroshi Katayama1, Haruhiko Fukuda1. 1. National Cancer Center Hospital, Tokyo, Japan. 2. Aichi Cancer Center Hospital, Nagoya, Japan. 3. Saitama Medical University International Medical Center, Hidaka, Japan. 4. Osaka International Cancer Institute, Osaka, Japan. 5. Shizuoka Cancer Center Hospital, Shizuoka, Japan. 6. Kanagawa Cancer Center, Kanagawa, Japan. 7. Yokohama City University Medical Center, Yokohama, Japan. 8. Yamagata Prefectural Central Hospital, Yamagata, Japan. 9. Tokyo Medical and Dental University, Tokyo, Japan. 10. Niigata Cancer Center Hospital, Niigata, Japan. 11. Ishikawa Prefectural Central Hospital, Kanazawa, Japan. 12. National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan. 13. Oita University Faculty of Medicine, Yufu, Japan. 14. Kochi Health Sciences Center, Kochi, Japan.
Abstract
PURPOSE: Adjuvant chemotherapy after hepatectomy is controversial in liver-only metastatic colorectal cancer (CRC). We conducted a randomized controlled trial to examine if adjuvant modified infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) is superior to hepatectomy alone for liver-only metastasis from CRC. PATIENTS AND METHODS: In this phase II or III trial (JCOG0603), patients age 20-75 years with confirmed CRC and an unlimited number of liver metastatic lesions were randomly assigned to hepatectomy alone or 12 courses of adjuvant mFOLFOX6 after hepatectomy. The primary end point of phase III was disease-free survival (DFS) in intention-to-treat analysis. RESULTS: Between March 2007 and January 2019, 300 patients were randomly assigned to hepatectomy alone (149 patients) or hepatectomy followed by chemotherapy (151 patients). At the third interim analysis of phase III with median follow-up of 53.6 months, the trial was terminated early according to the protocol because DFS was significantly longer in patients treated with hepatectomy followed by chemotherapy. With median follow-up of 59.2 months, the updated 5-year DFS was 38.7% (95% CI, 30.4 to 46.8) for hepatectomy alone compared with 49.8% (95% CI, 41.0 to 58.0) for chemotherapy (hazard ratio, 0.67; 95% CI, 0.50 to 0.92; one-sided P = .006). However, the updated 5-year overall survival (OS) was 83.1% (95% CI, 74.9 to 88.9) with hepatectomy alone and 71.2% (95% CI, 61.7 to 78.8) with hepatectomy followed by chemotherapy. In the chemotherapy arm, the most common grade 3 or higher severe adverse event was neutropenia (50% of patients), followed by sensory neuropathy (10%) and allergic reaction (4%). One patient died of unknown cause after three courses of mFOLFOX6 administration. CONCLUSION: DFS did not correlate with OS for liver-only metastatic CRC. Adjuvant chemotherapy with mFOLFOX6 improves DFS among patients treated with hepatectomy for CRC liver metastasis. It remains unclear whether chemotherapy improves OS.
PURPOSE: Adjuvant chemotherapy after hepatectomy is controversial in liver-only metastatic colorectal cancer (CRC). We conducted a randomized controlled trial to examine if adjuvant modified infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) is superior to hepatectomy alone for liver-only metastasis from CRC. PATIENTS AND METHODS: In this phase II or III trial (JCOG0603), patients age 20-75 years with confirmed CRC and an unlimited number of liver metastatic lesions were randomly assigned to hepatectomy alone or 12 courses of adjuvant mFOLFOX6 after hepatectomy. The primary end point of phase III was disease-free survival (DFS) in intention-to-treat analysis. RESULTS: Between March 2007 and January 2019, 300 patients were randomly assigned to hepatectomy alone (149 patients) or hepatectomy followed by chemotherapy (151 patients). At the third interim analysis of phase III with median follow-up of 53.6 months, the trial was terminated early according to the protocol because DFS was significantly longer in patients treated with hepatectomy followed by chemotherapy. With median follow-up of 59.2 months, the updated 5-year DFS was 38.7% (95% CI, 30.4 to 46.8) for hepatectomy alone compared with 49.8% (95% CI, 41.0 to 58.0) for chemotherapy (hazard ratio, 0.67; 95% CI, 0.50 to 0.92; one-sided P = .006). However, the updated 5-year overall survival (OS) was 83.1% (95% CI, 74.9 to 88.9) with hepatectomy alone and 71.2% (95% CI, 61.7 to 78.8) with hepatectomy followed by chemotherapy. In the chemotherapy arm, the most common grade 3 or higher severe adverse event was neutropenia (50% of patients), followed by sensory neuropathy (10%) and allergic reaction (4%). One patient died of unknown cause after three courses of mFOLFOX6 administration. CONCLUSION: DFS did not correlate with OS for liver-only metastatic CRC. Adjuvant chemotherapy with mFOLFOX6 improves DFS among patients treated with hepatectomy for CRC liver metastasis. It remains unclear whether chemotherapy improves OS.
Authors: Karen Bolhuis; G Emerens Wensink; Marloes A G Elferink; Marinde J G Bond; Willemieke P M Dijksterhuis; Remond J A Fijneman; Onno W Kranenburg; Inne H M Borel Rinkes; Miriam Koopman; Rutger-Jan Swijnenburg; Geraldine R Vink; Jeroen Hagendoorn; Cornelis J A Punt; Sjoerd G Elias; Jeanine M L Roodhart Journal: Cancers (Basel) Date: 2022-05-10 Impact factor: 6.575
Authors: Gabriel D Ivey; Fabian M Johnston; Nilofer S Azad; Eric S Christenson; Kelly J Lafaro; Christopher R Shubert Journal: Cancers (Basel) Date: 2022-02-20 Impact factor: 6.639
Authors: S Acciuffi; F Meyer; A Bauschke; R Croner; U Settmacher; A Altendorf-Hofmann Journal: J Cancer Res Clin Oncol Date: 2021-12-16 Impact factor: 4.553
Authors: Nathanael Raschzok; Sebastian Stintzing; Volker Heinemann; Geraldine Rauch; Jens Ricke; Matthias Guckenberger; Annika Kurreck; Annabel H S Alig; Arndt Stahler; Lars Bullinger; Moritz Schmelzle; Wenzel Schöning; Georg Lurje; Felix Krenzien; Oliver Haase; Beate Rau; Bernhard Gebauer; Igor M Sauer; Johann Pratschke; Dominik P Modest Journal: BMC Cancer Date: 2022-04-02 Impact factor: 4.430
Authors: Shahid Ahmed; Nicholas Bosma; Michael Moser; Shahida Ahmed; Bryan Brunet; Janine Davies; Corinne Doll; Dorie-Anna Dueck; Christina A Kim; Shuying Ji; Duc Le; Richard Lee-Ying; Howard Lim; John Paul McGhie; Karen Mulder; Jason Park; Deepti Ravi; Daniel J Renouf; Devin Schellenberg; Ralph P W Wong; Adnan Zaidi Journal: Curr Oncol Date: 2022-03-08 Impact factor: 3.677